Akebia Therapeutics, Inc. - COM (AKBA)

Historical Portfolio Holders from Q1 2014 to Q1 2024

All holders as of March 31, 2024: Q1 2024
Type / Class: Equity / COM
Shares, excl. options Q1 2024: 56.2 M
Holdings value Q1 2024: $103 M
Value change Q1 2024: +$1.91 M
Grand Portfolio weight change Q1 2024: +0%
Number of holders: 104
Number of buys Q1 2024: 59
Number of sells Q1 2024: -35
Average buys Q1 2024 %: +0%
Average sells Q1 2024 %: -0.001%
CUSIP: 00972D105

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Period	Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2024 Q1	56.2 M	$103 M	+$1.91 M	1.36 M	1.7 M	$1.83	104
2023 Q4	54 M	$66.9 M	+$4.18 M	407 K	512 K	$1.24	82
2023 Q3	50.8 M	$57.9 M	+$685 K	215 K	459 K	$1.14	73
2023 Q2	50.2 M	$46 M	-$1.39 M	104 K	242 K	$0.92	74
2023 Q1	49.1 M	$27.5 M	+$24.3 K	52.8 K	139 K	$0.56	61
2022 Q4	49.3 M	$28.5 M	+$1.76 M	23.5 K	95.6 K	$0.58	67
2022 Q3	51.1 M	$16.1 M	-$1.54 M	30 K	62 K	$0.32	71
2022 Q2	52.6 M	$18.6 M	-$7.47 M	43 K	87 K	$0.35	76
2022 Q1	80 M	$57.4 M	-$32.8 M	2.21 M	3.81 M	$0.72	114
2021 Q4	94.9 M	$214 M	-$4.44 M	585 K	4.51 M	$2.26	121
2021 Q3	91.4 M	$263 M	-$28.7 M	1.43 M	851 K	$2.88	112
2021 Q2	101 M	$381 M	+$8.31 M	3.15 M	1.78 M	$3.79	129
2021 Q1	98.4 M	$333 M	-$7.6 M	2.9 M	1.44 M	$3.38	128
2020 Q4	98.2 M	$275 M	-$4.62 M	2.13 M	2.82 M	$2.80	125
2020 Q3	97.3 M	$244 M	-$415 M	1.85 M	1.49 M	$2.51	147
2020 Q2	111 M	$1.51 B	+$246 M	2.38 M	8.39 M	$13.58	179
2020 Q1	81.4 M	$617 M	+$70.5 M	1.12 M	1.98 M	$7.58	141
2019 Q4	72.4 M	$458 M	-$7.38 M	1.17 M	603 K	$6.32	139
2019 Q3	83.3 M	$327 M	-$6.48 M	379 K	8.36 M	$3.92	137
2019 Q2	86.4 M	$418 M	-$1.55 M	593 K	10.5 M	$4.84	142
2019 Q1	75.6 M	$619 M	+$32.9 M	1.41 M	3.01 M	$8.19	160
2018 Q4	71.2 M	$393 M	+$199 M	1.09 M	3.8 M	$5.53	148
2018 Q3	40.8 M	$360 M	-$21.3 M	637 K	8.09 M	$8.83	122
2018 Q2	42.4 M	$423 M	-$3.99 M	423 K	8.87 M	$9.98	133
2018 Q1	42.8 M	$409 M	+$77.9 M	98 K	3 M	$9.53	143
2017 Q4	33.4 M	$497 M	+$18.7 M		226 K	$14.87	125
2017 Q3	29.9 M	$588 M	+$66.4 M	0	706 K	$19.67	116
2017 Q2	27.2 M	$391 M	+$96.2 M	287 K	813 K	$14.37	112
2017 Q1	20.5 M	$189 M	+$23.1 M	129 K	565 K	$9.20	83
2016 Q4	19.8 M	$207 M	+$3.87 M	534 K	877 K	$10.41	87
2016 Q3	18.8 M	$170 M	-$251 K	2.31 M	1.31 M	$9.05	80
2016 Q2	19.2 M	$144 M	-$12.7 M	2.78 M	1.77 M	$7.48	89
2016 Q1	20.7 M	$187 M	+$34.3 M	832 K	1.19 M	$9.01	89
2015 Q4	15.8 M	$204 M	+$34.8 M	242 K	1.14 M	$12.92	83
2015 Q3	13.6 M	$131 M	+$22.2 M	890 K	898 K	$9.66	79
2015 Q2	10.6 M	$109 M	+$58.5 M	723 K	875 K	$10.29	67
2015 Q1	6.12 M	$68 M	-$4.5 M	386 K	284 K	$11.11	56
2014 Q4	6.52 M	$75.9 M	-$6.54 M		355 K	$11.64	53
2014 Q3	5.6 M	$124 M	+$8.04 M		1.82 M	$22.13	48
2014 Q2	6.58 M	$183 M	+$181 M			$27.79	48
2014 Q1	104 K	$2.03 M	+$2.03 M			$19.56	3